Streetwise Reports' Article Archives — February 2021 back to current month (26)
Reliq Health Technologies reported it signed a new agreement with a Texas-based nephrology clinic to provide its iUGO Care platform to patients with chronic kidney disease.
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share.
Reliq Health introduces iUGO Home services and just added a care management network in California with 50 clinics and over 500 physicians.
This Dawson James report explains why ProPhase Labs is perfectly positioned to benefit from expanded COVID testing.
The many reasons why Columbia Care is 'due for a catch-up trade' are discussed in an Echelon Capital Markets report.
Shares of Owens & Minor Inc. soared to a new 52-week high after the company reported Q4/20 and FY/20 financial results that were boosted by a 58% gain in global products revenue and increases in elective medical procedures.
Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal.
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report.
Reliq Health Technologies reported it signed a new contract with a care management network for its iUGO Care platform to deliver customized healthcare to senior citizens in the Asian-American community throughout California.
Independent financial analyst Matt Badiali discusses DarioHealth's latest acquisition and what it means for the company's growth.
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development.
PAVmed Inc. shares reached a new 52-week high after the company reported that the first patient in the U.S. was successfully treated with its CarpX® Device, a minimally invasive carpal tunnel release surgical instrument.
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results.
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease.
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.
Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives.
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report.
DELIC aims to become a leader in psychedelic health and wellness clinics.
Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion.
ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class."
Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share.
Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients.
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|